相似文献
1
Activity of phenothiazines against medically important yeasts.
Antimicrob Agents Chemother. 1987 May;31(5):834-6. doi: 10.1128/AAC.31.5.834.
2
[Antimycotic activity in vitro and in vivo of 5-fluorocytosine on pathogenic strains of Candida albicans and Cryptococcus neoformans].
G Batteriol Virol Immunol. 1976 Jul-Dec;69(7-12):244-9.
3
Influence of culture medium on susceptibility testing with BAY n 7133 and ketoconazole.
J Clin Microbiol. 1986 Aug;24(2):269-71. doi: 10.1128/jcm.24.2.269-271.1986.
4
In vitro antifungal activity of eugenol and vanillin against Candida albicans and Cryptococcus neoformans.
Can J Microbiol. 1982 Nov;28(11):1235-41. doi: 10.1139/m82-184.
5
Amphotericin B and amphotericin B methyl ester ascorbate. I. Chemotherapeutic activity against Candida albicans, Cryptococcus neoformans, and Blastomyces dermatitidis in mice.
J Infect Dis. 1976 Nov;134(5):423-7. doi: 10.1093/infdis/134.5.423.
6
In vitro synergistic activity of ketoconazole with trifluoperazine and with chlorpromazine against medically important yeasts.
Chemotherapy. 1988;34(2):96-100. doi: 10.1159/000238554.
7
The influence of antifungal antibiotics on some determinants of virulence in Candida albicans and Cryptococcus neoformans cells.
Experientia. 1974 Oct 15;30(10):1210-1. doi: 10.1007/BF01923696.
8
Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and spp.
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.01921-19.
9
Cell cycle effects of the phenothiazines: trifluoperazine and chlorpromazine in Candida albicans.
FEMS Microbiol Lett. 2001 May 30;199(2):185-90. doi: 10.1111/j.1574-6968.2001.tb10672.x.
10
Susceptibility of Candida albicans and other yeasts to fluconazole: relation between in vitro and in vivo studies.
Rev Infect Dis. 1990 Mar-Apr;12 Suppl 3:S272-5. doi: 10.1093/clinids/12.supplement_3.s272.
引用本文的文献
1
Similarities and distinctions in the activation of the Pdr1 regulatory pathway by azole and non-azole drugs.
mSphere. 2024 Dec 19;9(12):e0079224. doi: 10.1128/msphere.00792-24. Epub 2024 Nov 18.
2
Similarities and distinctions in the activation of the Pdr1 regulatory pathway by azole and non-azole drugs.
bioRxiv. 2024 Sep 19:2024.09.19.613905. doi: 10.1101/2024.09.19.613905.
3
CWHM-974 is a fluphenazine derivative with improved antifungal activity against due to reduced susceptibility to multidrug transporter-mediated resistance mechanisms.
Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0056723. doi: 10.1128/aac.00567-23. Epub 2023 Sep 13.
4
Development of an Imaging Flow Cytometry Method for Fungal Cytological Profiling and Its Potential Application in Antifungal Drug Development.
J Fungi (Basel). 2023 Jun 30;9(7):722. doi: 10.3390/jof9070722.
5
CWHM-974 is a fluphenazine derivative with improved antifungal activity against due to reduced susceptibility to multidrug transporter-mediated resistance mechanisms.
bioRxiv. 2023 May 1:2023.05.01.538946. doi: 10.1101/2023.05.01.538946.
6
Repurposing and optimization of drugs for discovery of novel antifungals.
Drug Discov Today. 2022 Jul;27(7):2008-2014. doi: 10.1016/j.drudis.2022.04.021. Epub 2022 Apr 27.
7
A Yeast-Based Screening Unravels Potential Therapeutic Molecules for Mitochondrial Diseases Associated with Dominant Mutations.
Int J Mol Sci. 2021 Apr 24;22(9):4461. doi: 10.3390/ijms22094461.
8
Galleria mellonella as an insect model for P. destructans, the cause of White-nose Syndrome in bats.
PLoS One. 2018 Sep 5;13(9):e0201915. doi: 10.1371/journal.pone.0201915. eCollection 2018.
9
Virulence Factors as Targets for Anticryptococcal Therapy.
J Fungi (Basel). 2016 Nov 30;2(4):29. doi: 10.3390/jof2040029.
10
Antifungal Phenothiazines: Optimization, Characterization of Mechanism, and Modulation of Neuroreceptor Activity.
ACS Infect Dis. 2018 Apr 13;4(4):499-507. doi: 10.1021/acsinfecdis.7b00157. Epub 2017 Nov 2.
本文引用的文献
1
The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis.
Drugs. 1983 Feb;25 Suppl 1:35-51. doi: 10.2165/00003495-198300251-00005.
2
Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States.
Antimicrob Agents Chemother. 1982 Sep;22(3):482-7. doi: 10.1128/AAC.22.3.482.
3
Medical mycology in crisis.
J Lab Clin Med. 1983 Nov;102(5):685-93.
4
Antifungal agents used in systemic mycoses. Activity and therapeutic use.
Drugs. 1983 Jan;25(1):41-62. doi: 10.2165/00003495-198325010-00003.
5
Effects of phenothiazines on inhibition of plasma membrane ATPase and hyperpolarization of cell membranes in the yeast Saccharomyces cerevisiae.
Biochim Biophys Acta. 1984 Feb 15;769(3):601-10. doi: 10.1016/0005-2736(84)90059-2.
6
Membrane effects of phenothiazines in yeasts. I. Stimulation of calcium and potassium fluxes.
Biochim Biophys Acta. 1983 Sep 7;733(2):242-8. doi: 10.1016/0005-2736(83)90528-x.
7
Active extrusion of potassium in the yeast Saccharomyces cerevisiae induced by low concentrations of trifluoperazine.
J Gen Microbiol. 1985 Oct;131(10):2555-64. doi: 10.1099/00221287-131-10-2555.
8
Activity of compound G2 isolated from alfalfa roots against medically important yeasts.
Antimicrob Agents Chemother. 1986 Aug;30(2):290-4. doi: 10.1128/AAC.30.2.290.
9
Infections in cancer patients.
Cancer Treat Rev. 1975 Jun;2(2):89-128. doi: 10.1016/s0305-7372(75)80005-3.
10
Aspergillosis and other systemic mycoses. The growing problem.
JAMA. 1979 Oct 12;242(15):1631-5.
Zotero 插件